AxoGen

AxoGen Net Income

The Net Income of AxoGen (AXGN) as of Nov 7, 2026 is -15.70 M USD. In the previous year, Net Income was -9.96 M USD — a change of 57.60% (lower).

Net Income

-15.70 MUSD

YoY

57.60%

Last updated:

In 2025, AxoGen's profit amounted to -15.70 M USD, a 57.60% increase from the -9.96 M USD profit recorded in the previous year.

The AxoGen Net Income history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Income
Date
Net Income
Jan 1, 2023
-21.72 M USD
Jan 1, 2024
-9.96 M USD
Jan 1, 2025
-15.70 M USD
Jan 1, 2026 (e)
25.53 M USD
Jan 1, 2027 (e)
32.49 M USD
Jan 1, 2028 (e)
44.78 M USD
Jan 1, 2029 (e)
59.36 M USD
Jan 1, 2030 (e)
81.51 M USD
The AxoGen Net Income history
YEARNet IncomeYoY
est81.51 MUSD+37.31%
est59.36 MUSD+32.55%
est44.78 MUSD+37.86%
est32.49 MUSD+27.26%
est25.53 MUSD-262.56%
-15.70 MUSD+57.60%
-9.96 MUSD-54.12%
-21.72 MUSD-24.98%
-28.95 MUSD+7.27%
-26.99 MUSD+13.45%
-23.79 MUSD-18.32%
-29.12 MUSD+30.03%
-22.40 MUSD+114.42%
-10.45 MUSD-27.52%
-14.41 MUSD+7.90%
-13.36 MUSD-24.58%
-17.71 MUSD+21.66%
-14.56 MUSD+54.57%
-9.42 MUSD+2.16%
-9.22 MUSD+600.39%
-1.32 MUSD-108.75%
15.05 MUSD-1,545.78%
-1.04 MUSD+38.95%
-748,980.00USD+103.98%
-367,182.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

AxoGen Revenue

AxoGen Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
159.01 M USD
-20.76 M USD
-21.72 M USD
Jan 1, 2024
187.34 M USD
-1.76 M USD
-9.96 M USD
Jan 1, 2025
225.21 M USD
-7.85 M USD
-15.70 M USD
Jan 1, 2026 (e)
290.36 M USD
38.25 M USD
25.53 M USD
Jan 1, 2027 (e)
372.65 M USD
47.37 M USD
32.49 M USD
Jan 1, 2028 (e)
448.49 M USD
63.23 M USD
44.78 M USD
Jan 1, 2029 (e)
529.82 M USD
81.39 M USD
59.36 M USD
Jan 1, 2030 (e)
680.00 M USD
109.42 M USD
81.51 M USD

AxoGen Margins

AxoGen stock margins

The AxoGen margin analysis displays the gross margin, EBIT margin, as well as the profit margin of AxoGen. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for AxoGen.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2023
76.64 %
-13.06 %
-13.66 %
Jan 1, 2024
75.79 %
-0.94 %
-5.32 %
Jan 1, 2025
74.31 %
-3.49 %
-6.97 %
Jan 1, 2026 (e)
74.31 %
13.17 %
8.79 %
Jan 1, 2027 (e)
74.31 %
12.71 %
8.72 %
Jan 1, 2028 (e)
74.31 %
14.10 %
9.99 %
Jan 1, 2029 (e)
74.31 %
15.36 %
11.20 %
Jan 1, 2030 (e)
74.31 %
16.09 %
11.99 %

AxoGen Stock analysis

What does AxoGen do? AxoGen Inc is a US-American company based in Alachua, Florida. The company was founded in 2002 as a spin-off of the Grabowski Laboratory at the University of Florida. The goal of the company is to improve the regeneration of peripheral nerves through innovative products and solutions. AxoGen's business model is based on the development, production, and sale of biomaterial-based products for peripheral nerve regeneration. The company has three product categories: Avance nerve tissue, AxoGuard nerve wraps, and AxoTouch nerve testers. Avance nerve tissue is a proven technology for improving the regeneration of peripheral nerves. It consists of allogeneic nerve tissue from donors that has been prepared and sterilized for transplantation. Avance nerve tissue is used for surgical repair of nerve damage and has proven to be very effective in regenerating peripheral nerves. AxoGuard nerve wraps are silicone gels used for repairing nerve damage. They protect the delicate nerve fibers during the healing process and prevent scar formation. AxoGuard nerve wraps were designed to preserve the structure and function of nerves after surgical repair. AxoTouch nerve testers are devices used to measure nerve function. They are used to monitor and evaluate the integrity and function of peripheral nerves. This system is of great importance for assessing the surgical repair of nerve damage and monitoring the progress of healing. In recent years, AxoGen has experienced significant growth and has become a leading company in the field of peripheral nerve regeneration. The company has offices in the US and Europe and distributes its products worldwide. AxoGen is listed on the NASDAQ stock exchange and has a market capitalization of approximately $2.3 billion. AxoGen has made significant progress in recent years and has achieved several important milestones. In 2012, the company received approval from the US Food and Drug Administration (FDA) for the use of Avance nerve tissue for surgical repair of nerve damage. In 2014, AxoGen received CE marking for Avance nerve tissue and AxoGuard nerve wraps, thereby obtaining approval for the European market. AxoGen is continuously working on the development of new products and solutions to improve nerve regeneration. The company has a strong scientific foundation and is heavily involved in research. AxoGen also collaborates with leading scientists and clinics to improve its products and develop new applications. In summary, AxoGen is an innovative company specializing in the development and production of biomaterial-based products for peripheral nerve regeneration. The company has become a market leader in recent years and operates worldwide. AxoGen has brought proven technologies and products to the market that help improve nerve regeneration and enhance patients' quality of life. AxoGen is one of the most popular companies on Eulerpool.

Net Income Details

Understanding AxoGen's Profit Margins

The profit margins of AxoGen represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of AxoGen's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating AxoGen's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

AxoGen's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When AxoGen’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about AxoGen stock

Net Income of AxoGen is -15.70 M USD in 2025.

Net Income of AxoGen changed from -9.96 M USD to -15.70 M USD, representing a 57.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Income AxoGen since 2006 – with annual values, charts, and detailed analysis.

The achievement of a profit is the biggest goal of a company. The profit can be used for distribution or reinvestment. The profit (also called annual surplus or EAT, earnings after taxes) is the positive difference between income and expenses in a period as shown in the income statement. A negative annual surplus is called annual loss. Both performance measures are also combined under the neutral term annual result.

The Net Income is derived from all revenues / sales minus the expenses in the period under review. The following overview clearly shows which positions contribute to the annual surplus and where the differences lie compared to other variants of profit such as EBT, EBIT, and EBITDA.

Net Income's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Income's AxoGen historically and in real time.

The profit in evaluating a stock

History, usage, calculation, and application of earnings in securities trading.

The history of earnings dates back to the beginnings of modern business organization. Since the beginning of industrialization, companies have been established to generate profits, and profits have been considered an essential part of corporate management. In recent years, the importance of earnings for investors has continued to rise, as many investors seek to find stocks that generate solid earnings.

Use of Profits

In securities trading, profits are used to determine the value of a stock. A company that generates profits is considered financially healthy and its stocks are valued higher, while a company that does not generate profits is considered less reliable and therefore receives a lower valuation. Investors can review the profits of each company by examining the relevant documents such as the income statement, the annual financial statements, and the income tax audits.

Calculation of profits

There are several different ways to calculate profits. The simplest way to calculate profits is by calculating net earnings. Net earnings are calculated by subtracting the company's expenses from its revenue. Another way to calculate profits is by calculating operating income. Operating income is calculated by subtracting the company's materials costs and employee wages and salaries from its revenue.

Use of profits

There are many different ways in which investors can use profits when evaluating stocks. One example is calculating the price-to-earnings ratio (P/E ratio). The P/E ratio is the relationship between the price of a stock and the company's earnings. When calculating the P/E ratio, the stock price is divided by the company's earnings. A low P/E value indicates that the stock has a good price-performance ratio, and a high P/E value indicates that the stock has a poor price-performance ratio.

Advantages and disadvantages of using profits

There are many advantages to using earnings in securities trading. Firstly, investors can check the financial health of a company by analyzing earnings. Secondly, investors can make a better decision about the valuation of a stock by calculating the P/E ratio. Thirdly, investors can reduce their risk by choosing stocks with a low P/E ratio.

However, there are also some drawbacks to relying on profits. Firstly, profits can be distorted if a company increases its profits through cost-cutting measures. Secondly, profits can present an inaccurate picture of a company's financial health if they are not calculated correctly. Thirdly, profits may not always be a reliable indicator of a company's future, as they can easily fluctuate.

t('components_kpi_Explanation_34')

Overall, it can be said that profits in securities trading are an important indicator of a company's financial health. Investors can analyze profits to get a better understanding of the company's financial health and make informed decisions about stock valuation. However, there are some disadvantages to using profits as they can sometimes be distorted or inaccurate. Therefore, it is important for investors to be cautious and carefully analyze profits before making a decision to buy or sell stocks.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — AxoGen

All Key Metrics — AxoGen